Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

2.

A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function.

Takahashi N, Udagawa N, Suda T.

Biochem Biophys Res Commun. 1999 Mar 24;256(3):449-55. Review.

PMID:
10080918
3.

TRANCE is a TNF family member that regulates dendritic cell and osteoclast function.

Wong BR, Josien R, Choi Y.

J Leukoc Biol. 1999 Jun;65(6):715-24. Review.

PMID:
10380891
4.

Biology of the TRANCE axis.

Walsh MC, Choi Y.

Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):251-63. Review.

PMID:
12787563
5.

Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.

Hofbauer LC.

Eur J Endocrinol. 1999 Sep;141(3):195-210. Review. No abstract available.

6.

Regulation of the differentiation and function of osteoclasts.

Chambers TJ.

J Pathol. 2000 Sep;192(1):4-13. Review.

PMID:
10951393
7.

The molecular basis of osteoclast differentiation and activation.

Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N.

Novartis Found Symp. 2001;232:235-47; discussion 247-50. Review.

PMID:
11277084
8.

Osteoprotegerin ligand: a regulator of immune responses and bone physiology.

Kong YY, Boyle WJ, Penninger JM.

Immunol Today. 2000 Oct;21(10):495-502. Review. No abstract available.

PMID:
11071528
9.

RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.

Sordillo EM, Pearse RN.

Cancer. 2003 Feb 1;97(3 Suppl):802-12. Review.

10.

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ.

Endocr Rev. 1999 Jun;20(3):345-57. Review.

PMID:
10368775
11.

Perspective. Osteoclastogenesis and growth plate chondrocyte differentiation: emergence of convergence.

Odgren PR, Philbrick WM, Gartland A.

Crit Rev Eukaryot Gene Expr. 2003;13(2-4):181-93. Review.

PMID:
14696966
12.

Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.

Kostenuik PJ, Shalhoub V.

Curr Pharm Des. 2001 May;7(8):613-35. Review.

PMID:
11375772
13.

RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

Schoppet M, Preissner KT, Hofbauer LC.

Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53. Review.

14.

[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].

Ferrer Cañabate J, Tovar I, Martínez P.

An Med Interna. 2002 Aug;19(8):385-88. Review. Spanish. No abstract available.

PMID:
12244784
15.

Bone remodelling: a signalling system for osteoclast regulation.

Filvaroff E, Derynck R.

Curr Biol. 1998 Sep 24;8(19):R679-82. Review.

16.

Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.

Hofbauer LC, Heufelder AE.

J Mol Med (Berl). 2001 Jun;79(5-6):243-53. Review.

PMID:
11485016
17.

[Involvement of osteoclasts in cartilage and bone destruction in rheumatoid arthritis].

Hikita A, Tanaka S.

Nihon Rinsho. 2005 Jan;63 Suppl 1:84-6. Review. Japanese. No abstract available.

PMID:
15799323
18.
19.

Genetic regulation of osteoclast development and function.

Teitelbaum SL, Ross FP.

Nat Rev Genet. 2003 Aug;4(8):638-49. Review.

PMID:
12897775
20.

Supplemental Content

Support Center